GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » ROC (Joel Greenblatt) %

Nabriva Therapeutics (Nabriva Therapeutics) ROC (Joel Greenblatt) % : -18,898.23% (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Nabriva Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -18,898.23%.

The historical rank and industry rank for Nabriva Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

NBRVF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11856.2   Med: -4288.18   Max: 4446.28
Current: -673.98

During the past 10 years, Nabriva Therapeutics's highest ROC (Joel Greenblatt) % was 4446.28%. The lowest was -11856.20%. And the median was -4288.18%.

NBRVF's ROC (Joel Greenblatt) % is ranked worse than
60.14% of 1470 companies
in the Biotechnology industry
Industry Median: -336.79 vs NBRVF: -673.98

Nabriva Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 40.50% per year.


Nabriva Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Nabriva Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics ROC (Joel Greenblatt) % Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9,294.24 -4,400.17 -4,176.19 -782.72 -931.46

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -201.56 -222.21 -1,016.04 -12,531.86 -18,898.23

Competitive Comparison of Nabriva Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Nabriva Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nabriva Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's ROC (Joel Greenblatt) % falls into.



Nabriva Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.51 + 9.027 + 2.359) - (26.862 + 0 + 0.939)
=-5.905

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.439 + 0 + 3.331) - (25.063 + 0 + 0.944)
=-18.237

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Nabriva Therapeutics for the quarter that ended in Jun. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-48.096/( ( (0.263 + max(-5.905, 0)) + (0.246 + max(-18.237, 0)) )/ 2 )
=-48.096/( ( 0.263 + 0.246 )/ 2 )
=-48.096/0.2545
=-18,898.23 %

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nabriva Therapeutics  (OTCPK:NBRVF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Nabriva Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Executives
Hogan H Michael Iii officer: Chief Executive Officer C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio officer: Chief Financial Officer 15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan director
Broom Colin Md officer: Chief Executive Officer 119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow officer: Director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder officer: Chief Executive Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger officer: General Counsel and Corp Sec 633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia officer: Chief Medical Officer C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan officer: Chief Financial Officer C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino officer: Chief Commercial Officer 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty officer: General Counsel & Corp Sec. 1301 2ND AVE, SEATTLE WA 98101